Global Therapeutic Vaccines Market 2019-2023 – Increase in R&D Activities | Technavio

Development of novel therapies will drive market growth in North America

Oct. 31, 2019 15:00 UTC

Development of novel therapies will drive market growth in North America

LONDON--(BUSINESS WIRE)-- Technavio’s report on the therapeutic vaccines market is expected to grow by $978 million during 2019-2023. Diseases such as HIV, cancer, chronic diseases, and human papillomavirus are spreading at an alarming rate. This has created significant opportunities for the growth of the therapeutic vaccines market. Read More

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191031005660/en/

Technavio has announced its latest market research report titled global therapeutic vaccines market 2019-2023. (Graphic: Business Wire)

Technavio has announced its latest market research report titled global therapeutic vaccines market 2019-2023. (Graphic: Business Wire)

Therapeutic Vaccines Market: Increase in R&D Activities is Fostering Vaccine Innovation

Several diseases, including hepatitis B, Alzheimer’s, and cancer are becoming a significant public health concern across the world. This has led to the need to develop innovative therapeutic vaccines, thereby increasing R&D activities. Researchers have developed a new-generation vaccine known as NASVAC for chronic hepatitis B using a novel immunization route and an antigen called HBcAg.

Get a free sample analysis from the Therapeutic Vaccines Market

Therapeutic Vaccines Market: Strategic Alliances are Powering Vendors to Grow in the Market

The demand for therapeutic vaccines to treat various diseases such as cancer, autoimmune diseases, and infectious diseases is creating an opportunity for start-ups to enter the market and engage in strategic alliances. Vendors are collaborating to develop novel therapeutics, which are driving the growth of the market. For instance, in November 2018, GeoVax Labs Inc. and Virometix AG announced the commencement of a strategic collaboration to develop a therapeutic vaccine for human papillomavirus infection.

The North American region is dominating the global therapeutics vaccines market, with a market share of over 94%. The growth in the region is attributed to the growing prevalence of infectious, neurological, and autoimmune diseases.

Major vendors covered in the therapeutic vaccine market are Aimmune Therapeutics Inc., Immune Response BioPharma Inc., Inovio Pharmaceuticals Inc., Novartis AG, and Sanpower Group Co. Ltd.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Related Reports on Healthcare are:

  1. Global Therapeutic Beds Market 2019-2023
  2. Global Atherosclerosis Therapeutics Market 2019-2023
  3. Global Japanese Encephalitis Vaccines Market 2019-2023

Email us at media@technavio.com or register online for a brochure and synopsis

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

Technavio is an international consulting and market research firm dedicated to empowering confident strategic decisions within the medical device, dental, pharmaceutical, and more Healthcare industries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191031005660/en/

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com

Source: Technavio Research

Smart Multimedia Gallery

Technavio has announced its latest market research report titled global therapeutic vaccines market 2019-2023. (Graphic: Business Wire)

Powered by Business Wire

View this news release and multimedia online at:
http://www.businesswire.com/news/home/20191031005660/en

MORE ON THIS TOPIC